Real-Life Observational Study on Adult Acute Myeloid Leukemia Patients Treated With New Drugs at Italian Centers

What this Trial Is About

Researchers are conducting a multicenter observational study to evaluate how new drugs or drug combinations are used and how effective they are in treating adult patients with Acute Myeloid Leukemia AML. This study focuses on real-life treatment outcomes in patients treated at Italian GIMEMA centers, aiming to gain better understanding of novel therapies in everyday clinical practice. The study observes adult AML patients who start treatment with new drugs, either alone or in combination, as authorized by AIFA. Special attention is given to patients with specific genetic mutations such as FLT3 and IDH, treated with targeted drugs like gilteritinib and IDH inhibitors, as well as those on maintenance therapy with oral azacytidine or treated with glasdegib or gemtuzumab ozogamicin. No experimental treatments or additional visits beyond routine care are involved. Participants will be followed for at least 24 months using their regular clinical visits. Researchers will collect data on treatment use and measure outcomes such as overall survival at 24 months. The study does not require extra procedures beyond normal medical care, and participants health will be monitored through standard clinical practice during this period.

Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)